The Brighterside of News on MSN

New drug combo cuts risk of death for men with prostate cancer by 40%

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...
ascopubs.org

Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.

Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD). Concurrent mutations in DNA damage repair genes BRCA1, POLE, ATM and ...
ascopubs.org

Assessing the risk of cytokine release syndrome associated with the use of antineoplastic agents: A real-world pharmacovigilance study based on the FDA Adverse Event Reporting ...

Clinical outcomes for smokers with early-onset breast cancer: An analysis of the National Inpatient Sample. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...